Tiziana Life Sciences Ltd (TLSA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
55 Park Lane
London, W1K 1NA
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7495 2379
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
November 20, 2018
| Name | Title | Pay | Year Born |
| Ivor R. Elrifi | Chief Executive Officer & Executive Director | 131,000 | N/A |
| Gabriele Marco Antonio Cerrone | Founder & Executive Chairman | 0 | 1972 |
| William Edward Tente | Chief Regulatory Officer | 0 | 1958 |
| Keeren Shah | Chief Operating Officer & Chief Financial Officer | 0 | 1976 |
| Napoleone Ferrara | Member of Scientific Advisory Board | 0 | 1957 |
| Richard K. Kim | Chief Medical Officer | 0 | 1971 |
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.